Financial Summary (All financials)
| In millions, except per share items | Dec-31-17 | Dec-31-16 | Mar-31-15 | Mar-31-14 | Mar-31-13 | Mar-31-12 | Mar-31-11 | Mar-31-10 |
| Revenues | 4,764.0 | 4,455.0 | 3,113.0 | 2,925.2 | 3,206.1 | 4,613.4 | 4,842.3 | 4,807.7 |
| Revenue growth | 6.9% | | 6.4% | -8.8% | -30.5% | -4.7% | 0.7% | 4.9% |
| Cost of goods sold | 3,699.0 | 3,470.0 | 2,412.0 | 2,277.9 | 2,521.3 | 3,618.5 | 3,840.7 | 3,776.4 |
| Gross profit | 1,065.0 | 985.0 | 701.0 | 647.3 | 684.8 | 994.9 | 1,001.6 | 1,031.3 |
| Gross margin | 22.4% | 22.1% | 22.5% | 22.1% | 21.4% | 21.6% | 20.7% | 21.5% |
| Sales and marketing | 115.0 | 107.0 | 90.0 | 87.6 | 90.2 | 170.0 | 164.1 | 169.0 |
| Research and development | 115.0 | 116.0 | 49.0 | 48.5 | 56.0 | 66.4 | 65.0 | 75.9 |
| General and administrative | 306.0 | 290.0 | 305.0 | 209.3 | 200.6 | 262.9 | 246.8 | 236.1 |
| EBITA | 566.0 | 515.0 | 266.0 | 305.1 | 341.4 | 506.4 | 536.9 | 556.4 |
| EBITA margin | 11.9% | 11.6% | 8.5% | 10.4% | 10.6% | 11.0% | 11.1% | 11.6% |
| Amortization of intangibles | 37.0 | 43.0 | 9.0 | 3.1 | 3.3 | 10.8 | 11.1 | 6.1 |
| EBIT | 529.0 | 472.0 | 257.0 | 302.0 | 338.1 | 495.6 | 525.7 | 550.3 |
| EBIT margin | 11.1% | 10.6% | 8.3% | 10.3% | 10.5% | 10.7% | 10.9% | 11.4% |
| Pre-tax income | 462.0 | 404.0 | 107.0 | 222.2 | 260.9 | 407.0 | 438.7 | 435.4 |
| Income taxes | 152.0 | 111.0 | 37.0 | 62.5 | 73.7 | 143.8 | 125.0 | 156.5 |
| Tax rate | 32.9% | 27.5% | 34.6% | 28.2% | 28.3% | 35.3% | 28.5% | 35.9% |
| Earnings from continuing ops | 310.0 | 293.0 | -55.0 | 159.5 | 186.7 | 262.6 | 313.2 | 278.7 |
| Earnings from discontinued ops | | | 125.0 | 181.5 | 85.1 | | | |
| Net income | 310.0 | 293.0 | 70.0 | 340.9 | 271.8 | 262.6 | 313.2 | 278.7 |
| Net margin | 6.5% | 6.6% | 2.2% | 11.7% | 8.5% | 5.7% | 6.5% | 5.8% |
| |
| Diluted EPS | $5.35 | $5.01 | ($1.52) | $4.87 | $5.73 | $7.93 | $9.32 | $8.33 |
| Shares outstanding (diluted) | 57.9 | 58.5 | 36.1 | 32.7 | 32.6 | 33.1 | 33.6 | 33.5 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|